within Pharmacolibrary.Drugs.ATC.J;

model J01DC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00024166666666666667,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0181,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefaclor is a second-generation cephalosporin antibiotic used to treat a variety of bacterial infections, including respiratory tract infections, otitis media, skin and soft tissue infections, and urinary tract infections. It is administered primarily orally and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Qu, X, et al., &amp; Yang, H (2022). Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states. <i>Frontiers in pharmacology</i> 13 1012294–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2022.1012294\">10.3389/fphar.2022.1012294</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36278160/\">https://pubmed.ncbi.nlm.nih.gov/36278160</a></p></li><li><p>Welling, PG, et al., &amp; Wise, R (1979). The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin. <i>International journal of clinical pharmacology and biopharmacy</i> 17(9) 397–400. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/500261/\">https://pubmed.ncbi.nlm.nih.gov/500261</a></p></li><li><p>Nix, DE, et al., &amp; Affrime, MB (1997). Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. <i>Pharmacotherapy</i> 17(1) 121–125. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9017772/\">https://pubmed.ncbi.nlm.nih.gov/9017772</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DC04;
